HM20 Virtual product theaters: Aug. 25-27
Aug. 25, 2020. 12:00 p.m. – 1:00 p.m. ET
Medical Product Theater: Worsening Symptoms and Hospitalization for Heart Failure: Increased Risk of Poor Outcomes and Opportunities to Enhance Care
Objectives
- Discuss hospitalization as a pivotal point in the clinical trajectory of heart failure.
- Highlight strategies for improvement and optimization of the treatment plan for patients with heart failure.
- Provide practical guidance for identifying predictors of worsening heart failure and educating on the importance of patients’ self-management.
Speaker
Dr. William T. Abraham
William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE
Professor of Medicine, Physiology, and Cell Biology
College of Medicine Distinguished Professor
Division of Cardiovascular Medicine
The Ohio State University,
Columbus, Ohio
Sponsored by Novartis Pharmaceuticals, and the faculty will be compensated for time.
Aug. 26, 2020. 12:00 p.m. – 1:00 p.m. ET
Commercial Product Theater: A First Choice Treatment for the Inpatient Management of Stabilized Systolic HF Patients: An Evidence-Based Approach
Description
Patients hospitalized due to heart failure with reduced ejection fraction (HFrEF) are at considerable risk of readmission and mortality. This program will review the benefits and risks of starting therapy in the hospital to help prevent rehospitalization and reduce patient mortality.
Speaker
Hameed Ali, DO, SFHM
Clinical Assistant Professor of Medicine
Baylor Scott and White Health
Dallas, Texas
Sponsored by Novartis Pharmaceuticals, and the faculty will be compensated for time.
Aug. 27, 2020. 12:00 p.m. – 1:00 p.m. ET
Commercial Product Theater: Selecting A First-Choice Therapy for Systolic HF: Meeting the Burden of Proof
Description
Dr. Javed Butler
What is the burden of proof that needs to be met before a therapy can be selected for the treatment of systolic heart failure? Hear from Dr. Javed Butler, chairman of the Department of Medicine at the University of Mississippi Medical Center, to learn more about selecting a first-choice therapy for your patients with systolic heart failure.
In this program, Dr. Butler will discuss how aligning your therapy selection to pathophysiologic pathways for HFrEF, it is possible to reduce mortality and morbidity while providing a proven safety and tolerability profile.
Regardless of your patients’ previous heart failure treatment history, following this program, you can feel confident selecting your first-choice therapy for your patients with HFrEF.
Speaker
Javed Butler, MD, MPH, MBA
Chairman, Department of Medicine
University of Mississippi Medical Center,
Jackson, Mississippi
Sponsored by Novartis Pharmaceuticals, and the faculty will be compensated for time.
